IRIDEX (IRIX) Peer Comparison

$0.70

$0.00 (-0.10%)

As on 04-Sep-2026 16:28EDT

Market cap

$12 Mln

Revenue (TTM)

$52 Mln

P/E Ratio

--

P/B Ratio

331.2

Div. Yield

0 %

Edit

	IRIDEX (IRIX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	12	12,650	10,638	9,762	9,459
Revenue ($ Mln)	52	1,505	613	2,589	785
Net Profit ($ Mln)	-3.55	160.59	-188.05	222.40	41.54
Net Margin (%)	-6.88	10.67	-30.68	8.59	5.29
RoE (%)	-82.86	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.29	--	44.47	232.78
Price-To-Book	331.20	8.31	15.27	1.36	4.62

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	IRIDEX (IRIX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	51.57	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	32.89	483.98	127.96	1,245.50	384.30
Gross Profit	19.31	942.44	393.22	1,343.60	347.62
Operating Expenses	21.46	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-2.78	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-3.40	203.83	-192.83	350.40	52.15
Provision for Tax	0.15	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-3.55	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	IRIDEX (IRIX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	3.64	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	10.45	210.18	135.71	2,116.80	705.49
Current Liabilities	13.17	233.78	102.33	961.30	132.66
Total Liabilities	29.15	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	IRIDEX (IRIX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	3.30	630.60	404.74	7,231.50	1,749.63
Current Assets	23.96	1,344.12	515.78	3,020.50	1,200.55
Total Assets	29.15	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	4.01	212.71	102.84	1,203.70	690.94
Net Current Assets	0.00	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	IRIDEX (IRIX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-2.12	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-0.14	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	5.96	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	IRIDEX (IRIX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-54.80	11.76	-22.53	8.98	1.79
ROE (%)	-82.86	10.86	-28.10	3.04	1.97
ROA (%)	-7.35	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-2.75	13.63	-30.58	-5.99	9.87
Net Margin (%)	-6.88	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	IRIDEX (IRIX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	3.68	17.55	41.55	1.37	16.49
EBIT Growth (%)	73.74	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	34.88	8.72	-102.66	-30.32	400.42
EPS Growth (%)	36.85	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	-41.96	17.33	-12.65	2.19	2.16

Valuation Ratios

	IRIDEX (IRIX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-4.42	68.93	-34.59	--	189.42
Price / Book Value	331.20	8.31	15.27	--	4.62
Dividend Yield (%)	0.00	0.00	0.00	--	0.00
EV/EBITDA	103.77	55.45	-73.80	--	77.00
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	IRIDEX (IRIX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.00	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.04	0.01	0.00	0.06	0.01
Current Ratio	1.82	5.75	5.04	3.14	9.05
Quick Ratio	1.08	3.86	4.46	2.33	7.64
Interest Coverage	--	157.91	-38.31	8.18	1.92

Operating Efficiency Ratios

	IRIDEX (IRIX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	13.75	12.65	22.67	17.06	20.09
Asset Turnover	1.07	0.74	0.59	0.24	0.26
Receivable days	62.19	46.54	60.95	65.39	72.41
Inventory Days	102.31	331.92	193.84	221.09	146.53
Payable days	67.70	26.16	60.19	37.02	29.05
Cash Conversion Cycle	96.81	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly